Radius Health, Inc.
Dec 4, 2017

Radius Health Announces Five Presentations on elacestrant (RAD1901) at the San Antonio Breast Cancer Symposium (SABCS)

SABCS to include five abstracts from the development program for elacestrant as a potential treatment of ER-positive advanced breast cancer

Radius to host live webcast to discuss data presented at SABCS and provide a company update on December 7th at 8:00 p.m. CT / 9:00 p.m. ET

WALTHAM, Mass., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), announced today that it will present data from multiple clinical and pre-clinical studies of elacestrant, an oral selective estrogen degrader, in ER-positive breast cancer at the San Antonio Breast Cancer Symposium Meeting December 5-9, 2017 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

Details for the abstracts related to elacestrant are below:

Abstract Title: Elacestrant, a novel oral selective estrogen receptor degrader (SERD), decreases tumoral 18F-FES uptake in a phase 1 study of ER+, HER2 -, advanced breast cancer patients
Poster Session 1 (P1-10-04)
Session Title: Treatment: New Drugs and Treatment Strategies
Session Date: Wednesday, 12/6/2017
Session Time: 5:00 PM — 7:00 PM
Location: Hall 1

Abstract Title: Elacestrant, oral selective estrogen receptor degrader (SERD) in patients with ER positive (ER+)/HER2- advanced breast cancer: Updated phase 1 efficacy, safety and pharmacodynamic results
Spotlight Session 5 (PD5-08)
Session Title: Endocrine Therapy: SERDS for metastatic ER+ breast cancer
Session Date: Thursday, 12/7/2017
Session Time: 5:00 PM — 7:00 PM
Location: Ballroom 1&2 - 3rd Level

Abstract Title: New oral SERD elacestrant (RAD1901) shows efficacy in breast cancer models harbouring ESR1 mutations and enhances the antiproliferative activity of mTORC1 and CDK4/6 inhibitors
Poster Session 4 (P4-04-09)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: Friday, 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstract Title: Anti-tumor activity of elacestrant (RAD1901) in combination with alpelisib (BYL-719) in patient-derived xenograft models of ER+ breast cancer
Poster Session 4 (P4-04-14)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstract Title: Elacestrant (RAD1901) demonstrates anti-tumor activity in a fulvestrant-resistant PDX model
Poster Session 4 (P4-04-17)
Session Title: Tumor Cell and Molecular Biology: Endocrine Therapy and Resistance
Session Date: 12/8/2017
Session Time: 7:00 AM — 9:00 AM
Location: Hall 1

Abstracts for the posters can be found on the SABCS website at http://www.abstracts2view.com/sabcs/

Webcast Information

Radius will host an investor meeting and webcast on Thursday, December 7th to highlight the elacestrant data presented at SABCS and provide a company update at 8:00 p.m. CT / 9:00 p.m. ET.

The live webcast titled "Oncology Program Update from San Antonio Breast Cancer Symposium — 2017" will be available at https://edge.media-server.com/m6/p/ycgfk3pd or by visiting the Investors section of Radius' website at http://ir.radiuspharm.com/events.cfm.

A replay of the webcast will be archived on Radius' website for 30 days following the presentation.

About Elacestrant (RAD1901)
Elacestrant is a selective estrogen receptor degrader (SERD), which is being evaluated for potential use as a once daily oral treatment for hormone-receptor positive breast cancer. Elacestrant is currently being investigated for potential use in women with advanced estrogen receptor positive, HER2 negative, breast cancer, the most common form of the disease. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer.

Additional information on the clinical trial program of elacestrant (RAD1901) is available on www.clinicaltrials.gov.

About Radius

Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer, and vasomotor symptoms in postmenopausal women; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.

Forward-Looking Statements 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the progress of abaloparatide-SC in the regulatory process with the EMA, the progress in the development of our product candidates, including abaloparatide-TD, elacestrant (RAD1901) and RAD140, and the potential clinical uses and therapeutic and other benefits of our product candidates, including abaloparatide-TD, elacestrant and RAD140.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we expect to need to raise additional funding, which may not be available; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of TYMLOS, and our inability to ensure that TYMLOS will obtain regulatory approval outside the U.S. or be successfully commercialized in any market in which it is approved, including as a result of risk related to coverage, pricing and reimbursement; risks related to competitive products and any collaboration agreements failing to be successful; risks related to clinical trials, including our reliance on third parties to conduct key portions of our clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates or during commercialization, if approved; risks related to manufacturing, supply and distribution; and the risk of litigation or other challenges regarding our intellectual property rights. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, or SEC, including under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the period ending June 30, 2017 and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release.  Any such forward-looking statements represent management's estimates as of the date of this press release.  While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.  These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Investor & Media Relations Contact:
Alex Fudukidis
Email: alex.fudukidis@russopartnersllc.com
Phone: 646-942-5632